PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22.64%
Negative EBIT growth while Biotechnology median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-22.65%
Negative operating income growth while Biotechnology median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-23.20%
Negative net income growth while Biotechnology median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-16.67%
Negative EPS growth while Biotechnology median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-22.50%
Negative diluted EPS growth while Biotechnology median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
5.52%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
0.56%
Diluted share change of 0.56% while Biotechnology median is zero. Walter Schloss might see a slight difference in equity issuance policy.
-100.00%
Dividend cuts while Biotechnology median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
-16.84%
Negative OCF growth while Biotechnology median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-16.73%
Negative FCF growth while Biotechnology median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6820.22%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
80.75%
OCF/share CAGR of 80.75% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
65.01%
3Y OCF/share growth of 65.01% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-4282.29%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
64.75%
Net income/share CAGR of 64.75% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
77.40%
3Y net income/share CAGR of 77.40% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
285.15%
Equity/share CAGR of 285.15% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-96.49%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-92.46%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.33%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-49.30%
Negative BV/share change while Biotechnology median is -1.48%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-8.76%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
23.04%
R&D growth of 23.04% while Biotechnology median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
21.61%
SG&A growth of 21.61% while Biotechnology median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.